Passage Bio Inc

Passage Bio’s recent earnings miss has shifted analyst sentiment, prompting downgrades and trimmed price targets amid continued institutional support and a focus on rare CNS gene therapies.

Passage Bio pioneers AAV‑gene therapy for rare CNS disorders, blending breakthrough science with dynamic market moves—discover its potential impact and investor outlook.

Passage Bio, Inc. is a pioneering biotech company dedicated to developing innovative genetic therapies for rare monogenic central nervous system diseases, with a strong focus on AAV-delivered therapeutics and a promising future outlook.